36 related articles for article (PubMed ID: 1933801)
21. Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group.
Sondak VK; Kopecky KJ; Liu PY; Fletcher WS; Harvey WH; Laufman LR
Anticancer Drugs; 1994 Apr; 5(2):147-50. PubMed ID: 8049497
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of didemnin B in advanced colorectal cancer.
Jones DV; Ajani JA; Blackburn R; Daugherty K; Levin B; Patt YZ; Abbruzzese JL
Invest New Drugs; 1992 Aug; 10(3):211-3. PubMed ID: 1428730
[TBL] [Abstract][Full Text] [Related]
23. Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide.
Dorr FA; Kuhn JG; Phillips J; von Hoff DD
Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1699-706. PubMed ID: 3208814
[TBL] [Abstract][Full Text] [Related]
24. Phase I clinical study of didemnin B. A National Cancer Institute of Canada Clinical Trials Group study.
Maroun JA; Stewart D; Verma S; Eisenhauer E
Invest New Drugs; 1998; 16(1):51-6. PubMed ID: 9740544
[TBL] [Abstract][Full Text] [Related]
25. Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting.
Shin DM; Holoye PY; Murphy WK; Forman A; Papasozomenos SC; Hong WK; Raber M
Cancer Chemother Pharmacol; 1991; 29(2):145-9. PubMed ID: 1662119
[TBL] [Abstract][Full Text] [Related]
26. A phase I clinical trial of didemnin B.
Stewart JA; Low JB; Roberts JD; Blow A
Cancer; 1991 Dec; 68(12):2550-4. PubMed ID: 1933801
[TBL] [Abstract][Full Text] [Related]
27. Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent.
Chun HG; Davies B; Hoth D; Suffness M; Plowman J; Flora K; Grieshaber C; Leyland-Jones B
Invest New Drugs; 1986; 4(3):279-84. PubMed ID: 3546184
[TBL] [Abstract][Full Text] [Related]
28. Phase II clinical trial of didemnin B in previously treated small cell lung cancer.
Shin DM; Holoye PY; Forman A; Winn R; Perez-Soler R; Dakhil S; Rosenthal J; Raber MN; Hong WK
Invest New Drugs; 1994; 12(3):243-9. PubMed ID: 7896544
[TBL] [Abstract][Full Text] [Related]
29. Natural products as probes of cell biology: 20 years of didemnin research.
Vera MD; Joullié MM
Med Res Rev; 2002 Mar; 22(2):102-45. PubMed ID: 11857636
[TBL] [Abstract][Full Text] [Related]
30. Merbarone: an antitumor agent entering clinical trials.
Glover A; Chun HG; Kleinman LM; Cooney DA; Plowman J; Grieshaber CK; Malspeis L; Leyland-Jones B
Invest New Drugs; 1987; 5(2):137-43. PubMed ID: 3308762
[TBL] [Abstract][Full Text] [Related]
31. Echinomycin: the first bifunctional intercalating agent in clinical trials.
Foster BJ; Clagett-Carr K; Shoemaker DD; Suffness M; Plowman J; Trissel LA; Grieshaber CK; Leyland-Jones B
Invest New Drugs; 1985; 3(4):403-10. PubMed ID: 3910610
[TBL] [Abstract][Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
